Compare · NVO vs QUCY
NVO vs QUCY
Side-by-side comparison of Novo Nordisk A/S (NVO) and Mainz Biomed N.V. (QUCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and QUCY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $199.97B, about 1675.1x QUCY ($119.4M).
- Over the past year, NVO is down 17.9% and QUCY is down 15.4% - QUCY leads by 2.5 points.
- QUCY has been more active in the news (8 items in the past 4 weeks vs 6 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for QUCY).
- Company
- Novo Nordisk A/S
- Mainz Biomed N.V.
- Price
- $44.57-1.33%
- $1.41-1.06%
- Market cap
- $199.97B
- $119.4M
- 1M return
- -6.62%
- +1.81%
- 1Y return
- -17.90%
- -15.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 8
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest QUCY
- Quantum Cyber Acquires NVIDIA A100 AI Compute Cluster to Power Its Swarm Operating System
- Quantum Cyber Invites Qualified Foundries, and Prototype-Development Partners to Apply for Its Quantum-Photonic Antenna Manufacturing Program; Responses Due September 18, 2026
- Precision Agriculture Goes Airborne as Drone Surveying Market Accelerates Toward Double-Digit Growth
- Quantum Cyber Appoints Tzvi Lev as Head of Sales, Middle East to Lead GCC Commercial Expansion of Its Autonomous Defense Platform
- Quantum Cyber Completes Purchase and Installation of 80-Unit 3D Printing Drone Production Farm at Its Bridgeport, Connecticut Manufacturing Facility
- Quantum Cyber Appoints Veteran Distribution Executive Dennis Schnur as Head of U.S. Sales as Company Advances Toward Commercialization of Domestic Drone Production
- Quantum Cyber Rejects Threat of Future Publications from Short-Seller Adam Gefvert Demanding Withdrawal of $5.69 Million Lawsuit
- Quantum Cyber to Participate in Invitation-Only 1640 Society Hamptons Family Office Wealth Forum 2026
- SEC Form 10-Q filed by Mainz Biomed N.V.
- Quantum Cyber Unveils the Quantum Photonic Antenna and Publishes Inaugural Technical White Paper Detailing the Quantum Layer of Its Autonomous Defense Platform